ClinicalTrials.Veeva

Menu

Study of the Utility of the BOMET-QOL Questionnaire Patients With Breast Cancer and Bone Metastasis (MAbomet)

S

Spanish Breast Cancer Research Group (GEICAM)

Status

Completed

Conditions

Breast Carcinoma Metastatic to the Bone

Treatments

Diagnostic Test: BOMET-QoL questionnaire

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT03847220
Mabomet

Details and patient eligibility

About

Epidemiological, prospective and multicenter study to evaluate the utility of the BOMET-QoL questionnaire in patients with breast cancer (BC) and bone metastases (BM).

Full description

Population: Patients over 18 with breast cancer and bone metastasis.

Inclusion criteria:

Patient over 18 years of age. Patient diagnosed with breast cancer (BC) and bone metastases (BM). Patient who has granted informed consent in writing to participate in the study. Patient capable of understanding and completing the questionnaires.

Exclusion criteria:

Patient with another type of disease that, in the investigator's opinion, could mask the study results. Patients with a life expectancy of less than 8 months. Patient who is participating in a clinical trial with an unregistered drug at the start of the study.

Enrollment

241 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient over 18 years of age.
  • Patient diagnosed with BC and BM.
  • Patient who has granted informed consent in writing to participate in the study.
  • Patient capable of understanding and completing the questionnaires

Exclusion criteria

  • Patient with another type of disease that, in the investigator's opinion, could mask the study results.
  • Patients with a life expectancy of less than 8 months.
  • Patient who is participating in a clinical trial with an unregistered drug at the start of the study.

Trial contacts and locations

15

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems